A Study to Evaluate the Bioequivalence (BE) and the Food Effect of TAK-438ASA Tablet

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

276 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-08

Study Completion Date

2018-10-12

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purposes of this study are to evaluate BE between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 milligram (mg) and aspirin enteric-coated tablet 100 mg in Japanese healthy adult men (Study 1), and to evaluate the effects of food on the pharmacokinetics of TAK-438ASA tablet in Japanese healthy adult men (Study 2).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bioavailability and Effect of Food on TAK-385 Tablet Formulations in Healthy Participants

NCT02396147

Healthy Volunteers

COMPLETED PHASE1

Randomized, Crossover Bioequivalence Study of PL-ASA Versus Immediate Release Aspirin in Healthy Volunteers.

NCT05055752

Bioequivalence

COMPLETED PHASE1

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093

Pharmacology, Clinical

COMPLETED PHASE1

Bioavailability and Food Effect Study of Two Formulations of TAK-906

NCT04831502

Healthy Volunteers

WITHDRAWN PHASE1

A Study to Learn if There is a Difference in the Blood Levels of Acetylsalicylic Acid When Taken as Different Chewable Tablets on an Empty Stomach by Healthy Participants

NCT06655194

Bioequivalence Healthy Volunteers Platelet Aggregation Inhibition

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The drug under investigation in this study is called TAK-438ASA. TAK-438ASA is being tested in Japanese healthy adult men. This study consists of two studies to evaluate bioequivalence (Study 1) and the effects of food (Study 2). Study 1 (split into a Pilot phase and a Pivotal phase) will look at bioequivalence between a single-dose of TAK-438ASA tablet versus a single-dose combination of TAK-438 tablet 10 mg and aspirin enteric-coated tablet 100 mg. Study 2 will look at the effects of food on the pharmacokinetics of TAK-438ASA tablet.

The study will enroll up to 440 participants in total (Study 1 + 2). For Study 1, 12 participants per group (24 participants in total) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups for the pilot study to estimate the sample size of Pivotal study. After pilot study, 202 participants as a maximum per group (404 participants in total) will be randomly assigned to one of the two treatment groups:

* TAK-438ASA tablet (Period 1) + TAK-438 10 mg tablet and Aspirin 100 mg tablet (Period 2)
* TAK-438 10 mg tablet and Aspirin 100 mg tablet (Period 1) + TAK-438ASA tablet (Period 2)

For Study 2, 6 participants per group (12 participants in total) will be randomly assigned (by chance, like flipping a coin) to one of the two treatment groups:

* TAK-438ASA tablet (Fasted condition) + TAK-438ASA tablet (Fed condition)
* TAK-438ASA tablet (Fed condition) + TAK-438ASA tablet (Fasted condition) This single-center trial will be conducted in Japan. The overall time to participate in this study is approximately 18 days. Participants will make two visits to the clinic and be hospitalized for eight days in total.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pilot phase of Study 1,TAK-438ASA + TAK-438 and Aspirin

One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

TAK-438

Intervention Type DRUG

TAK-438 tablet.

Aspirin

Intervention Type DRUG

Aspirin enteric-coated tablet.

Pilot phase of Study 1,TAK-438 and Aspirin + TAK-438ASA

One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pilot phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by, one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pilot phase of Study 1 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

TAK-438

Intervention Type DRUG

TAK-438 tablet.

Aspirin

Intervention Type DRUG

Aspirin enteric-coated tablet.

Pivotal phase of Study 1, TAK-438ASA + TAK-438 and Aspirin

One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

TAK-438

Intervention Type DRUG

TAK-438 tablet.

Aspirin

Intervention Type DRUG

Aspirin enteric-coated tablet.

Pivotal phase of Study 1, TAK-438 and Aspirin + TAK-438ASA

One TAK-438 10 mg tablet and one aspirin 100 mg tablet, orally without breakfast, on Day 1 of Period 1 in the Pivotal phase of Study 1 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in the Pivotal phase of Study 1 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

TAK-438

Intervention Type DRUG

TAK-438 tablet.

Aspirin

Intervention Type DRUG

Aspirin enteric-coated tablet.

Study 2,TAK-438ASA (Fasted + Fed condition)

One TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 2 in Study 2 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

Study 2,TAK-438ASA (Fed + Fasted condition)

One TAK-438ASA tablet, orally 30 minutes after breakfast, on Day 1 of Period 1 in Study 2 (Day 1), followed by a washout period (Days 2 to 15), followed by one TAK-438ASA tablet, orally without breakfast, on Day 1 of Period 2 in Study 2 (Day 16).

Group Type EXPERIMENTAL

TAK-438ASA

Intervention Type DRUG

TAK-438ASA tablet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TAK-438ASA

TAK-438ASA tablet.

Intervention Type DRUG

TAK-438

TAK-438 tablet.

Intervention Type DRUG

Aspirin

Aspirin enteric-coated tablet.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. In the opinion of the investigator or sub-investigator, participants are capable of understanding the procedures required for the study and complying with its requirements.
2. Participants sign and date an informed consent form by themselves prior to the initiation of any study procedures.
3. Japanese healthy men aged greater than or equal to (\>=) 20 and less than or equal to (=\<) 60, inclusive, at the time of consent.
4. Body weight \>=50 kilogram (kg) as well as body mass index (BMI) \>=18.5 kilogram per meter square (kg/m\^2) and =\<25.0 kg/m\^2 at screening test.

Exclusion Criteria

1. Participants who received study drug within 16 weeks (112 days) prior to the start of study treatment in Period 1.
2. Participants who received TAK-438 or aspirin in a previous study.
3. Staffs at the study site and their family, or participants who depend on the study-related staffs at the study site (example, husband and wife, parents, children, brothers and sisters), or participants who may be constrained to consent to the study.
4. Participants with uncontrolled and clinically significant neurological, cardiovascular, lung, hepatic, renal, metabolic, gastrointestinal, urinary or endocrine disease, or other abnormalities (except for diseases investigated) that might affect the study participation or impact the results of the study.
5. Participants with a previous or current history of aspirin asthma (asthmatic attack induced by non-steroidal anti-inflammatory drugs, etc.).
6. Participants with hypersensitivity for components of TAK-438 tablet or aspirin enteric-coated tablet, or salicylic acid-based products.
7. Positive result in urinary test for illegal drug abuse at screening.
8. Participants who have a history of illegal drug abuse or alcoholism within the past 2 years prior to the screening visit, or who are not willing to refrain from alcohol consumption and drug use during the study period.
9. Participants who ingested a medicine, a supplement or food forbidden to be used in combination during the specified time period.
10. Participants with a current history or recent episodes (within the past 6 months) of gastrointestinal diseases (malabsorption, gastroesophageal reflux, peptic ulcer disease, erosive oesophagitis), frequent (at least once per week) heartburn or surgical intervention that might affect drug absorption.
11. Participants with a history of cancer, except for basal cell carcinoma in remission for \>=5 years prior to Day 1.
12. Positive results at screening for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen, or serological test for syphilis.
13. Participants who have difficulties in blood draw from peripheral veins.
14. Participants who had \>=200 milliliter (mL) of whole blood drawn within 4 weeks (28 days) prior to the start of study treatment in Period 1 or who had \>=400 mL of whole blood drawn within 12 weeks (84 days) prior to the start of study treatment in Period 1.
15. Participants who had a total of \>=800 mL of whole blood drawn within 52 weeks (364 days) prior to the start of study treatment in Period 1.
16. Participants who had blood components drawn within 2 weeks (14 days) prior to the start of study treatment in Period 1.
17. Clinically significant abnormalities in electrocardiogram at screening or admission (Day -1).
18. Participants with abnormal laboratory parameters suggestive of clinically significant underlying diseases or who have abnormal values in the following measures at screening: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) over the upper limit of normal.
19. Participants who are unlikely to comply with the protocol or deemed ineligible due to other reasons by the principal investigator or other investigators.

Minimum Eligible Age

20 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes